Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Consensus Price Target of $103.00

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty-two brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $103.00.

ZBH has been the topic of several analyst reports. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Stifel Nicolaus raised their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Canaccord Genuity Group lifted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a research report on Monday.

Insider Buying and Selling

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $1,344,282,000. State Street Corp boosted its stake in shares of Zimmer Biomet by 0.6% in the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after purchasing an additional 52,044 shares during the period. Franklin Resources Inc. grew its stake in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after acquiring an additional 2,017,857 shares in the last quarter. Geode Capital Management LLC grew its stake in Zimmer Biomet by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after purchasing an additional 36,611 shares in the last quarter. Finally, Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet during the second quarter worth approximately $328,578,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH opened at $91.51 on Tuesday. The stock’s 50-day moving average price is $96.27 and its 200 day moving average price is $91.25. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $106.88. The firm has a market cap of $17.45 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.72 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts expect that Zimmer Biomet will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.